Insights
Search Results
Client Highlights
11.17.25
Wilson Sonsini Advises Kura Oncology on Patent and Trademark Matters Related to KOMZIFTI’s FDA Approval
On November 13, 2025, Kura Oncology (Kura) and Kyowa Kirin announced that the U.S. Food and Drug Administration (FDA) has granted full approval for KOMZIFTI™ (ziftomenib). Wilson Sonsini Goodrich & Rosati advised Kura on patent and trademark matters.
Client Highlights
11.22.24
Firm Advises Kura Oncology on Global Strategic Collaboration with Kyowa Kirin
On November 20, 2024, Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, announced that they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Wilson Sonsini Goodrich & Rosati advised Kura on the transaction and has advised the company on IP matters since its founding in 2014.
Client Highlights
10.15.24
Wilson Sonsini Advises Crinetics Pharmaceuticals on Patent Matters Related to Upsized $500 Million Common Stock Offering
On October 8, 2024, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the pricing of an upsized underwritten public offering of 10 million shares of its common stock at a price to the public of $50.00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. Wilson Sonsini Goodrich & Rosati is advising Crinetics on patent matters related to the transaction.
Client Highlights
12.26.23
Wilson Sonsini Advises RayzeBio on Patent Matters Related to Acquisition by Bristol Meyers Squibb
On December 26, 2023, Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, and RayzeBio Inc. (Nasdaq: RYZB), a clinical-stage radiopharmaceutical therapeutics company, announced that they had entered into a definitive agreement pursuant to which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati advised RayzeBio on patent matters related to the transaction.
Client Highlights
9.15.23
Firm Advises RayzeBio on IP Matters Related to $311 Million IPO
On September 14, 2023, RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the pricing of its upsized $311 million initial public offering of 17,277,600 shares of common stock at a price to the public of $18.00 per share. RayzeBio is offering 16,114,600 shares of common stock and the selling stockholder named in the prospectus is offering 1,163,000 shares of common stock. Wilson Sonsini Goodrich & Rosati advised RayzeBio on all IP matters leading up to and with respect to the IPO.
The gross proceeds to RayzeBio from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RayzeBio, are expected to be approximately $290.1 million. In addition, RayzeBio has granted the underwriters a 30-day option to purchase up to an additional 2,591,640 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds to RayzeBio from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RayzeBio, are expected to be approximately $290.1 million. In addition, RayzeBio has granted the underwriters a 30-day option to purchase up to an additional 2,591,640 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Client Highlights
9.14.22
Wilson Sonsini Advises RayzeBio on Patent Matters Related to $160 Million Series D
On September 13, 2022, RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced a $160 million Series D financing co-led by Viking Global Investors, Sofinnova Investments, and Wellington Management. Additional new investors Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital, and an undisclosed global investor also participated, as did RayzeBio’s current investors. With this latest financing, RayzeBio has now raised $418 million since beginning operations in August 2020.
According to RayzeBio’s president and CEO, Ken Song, M.D., the financing provides the company the ability to further expand its leadership in targeted radiopharmaceuticals and allows it to reach several major value inflection points both clinically and operationally. RayzeBio has advanced its lead drug candidate, RYZ101, which delivers Ac225, a highly potent alpha-emitting radioisotope, into clinical trials for multiple solid tumor indications. A Phase 1b clinical trial is currently enrolling patients with neuroendocrine tumors and Phase 3 studies could begin as early as 2023.
Wilson Sonsini’s patents and innovations group, led by Ying Chen, represented RayzeBio in patent matters related to the transaction. Also included on the team were Michael Hostetler, Céline Bonnefous, and Michael Wormald.
For more information, please see RayzeBio’s news release. Additional information is available in Endpoints News.
According to RayzeBio’s president and CEO, Ken Song, M.D., the financing provides the company the ability to further expand its leadership in targeted radiopharmaceuticals and allows it to reach several major value inflection points both clinically and operationally. RayzeBio has advanced its lead drug candidate, RYZ101, which delivers Ac225, a highly potent alpha-emitting radioisotope, into clinical trials for multiple solid tumor indications. A Phase 1b clinical trial is currently enrolling patients with neuroendocrine tumors and Phase 3 studies could begin as early as 2023.
Wilson Sonsini’s patents and innovations group, led by Ying Chen, represented RayzeBio in patent matters related to the transaction. Also included on the team were Michael Hostetler, Céline Bonnefous, and Michael Wormald.
For more information, please see RayzeBio’s news release. Additional information is available in Endpoints News.